Hangzhou Tigermed Consulting Co., Ltd. announced on November 10, 2026, its proposal to participate in the privatization of controlled subsidiary Frontage Holdings Corporation and subsequently divest Frontage's overseas laboratory services business to Charles River Laboratories International, Inc. and Dr. Song Li, while retaining Frontage's China business.

Key Highlights

  • Privatization proposal: Tigermed intends to participate in the privatization of Frontage Holdings Corporation (Stock Code: 1521.HK) through its wholly-owned subsidiary Hongkong Tigermed Co., Limited.
  • Overseas business divestiture: Frontage's overseas laboratory services business, covering preclinical research, laboratory testing, chemistry and CMC services, is proposed to be divested to Charles River Laboratories International, Inc. (NYSE:CRL) and Dr. Song Li, Chairman of the Board of Frontage, and his trusts.
  • China business retained: Tigermed proposes to retain Frontage's China laboratory services business following the asset restructuring.
  • Long-held stake: According to the filing, Tigermed acquired a controlling stake in Frontage in 2014.
  • Expected financial impact: Tigermed is expected to receive proceeds and record investment gains through the privatization and subsequent asset restructuring, with the filing noting that gains on disposal create value for Tigermed shareholders.
  • Subject to conditions: The proposed privatization and subsequent asset restructuring remain subject to satisfaction of relevant conditions precedent and implementation requirements.

Tigermed's Strategic Rationale for Frontage Restructuring

According to the announcement, Tigermed (Stock Codes: 300347.SZ / 3347.HK) described the overseas laboratory services business proposed for divestiture as being "of a different nature to Tigermed's core clinical CRO business." The filing stated that divesting overseas laboratory facilities located outside China is intended to allow Tigermed to "optimize its strategic planning, capital allocation and operational improvement," which the company characterized as aligning with its long-term strategy.

The filing indicated that the proposed divestment would enable Tigermed to further focus on clinical CRO business, optimize resource allocation, enhance operational efficiency, and strengthen clinical service capabilities in China markets. By consolidating the retained laboratory services business in China, Tigermed said it aims to "streamline business management, strengthen end-to-end capabilities across the full clinical trial value chain, and better advance its long-term strategic objectives."

Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed, was quoted in the filing describing the transaction as "an important strategic decision in advancing Tigermed's long-term development strategy" and said it "embodies our commitment to proactively transforming and optimizing our business portfolio." The filing noted that the opportunity to redeploy proceeds toward Tigermed's core clinical CRO business could create further value for shareholders, though the transaction remains conditional on the satisfaction of relevant conditions precedent.

What Was Disclosed

Tigermed disclosed a proposal to privatize subsidiary Frontage Holdings and divest Frontage's overseas laboratory services business to Charles River Laboratories and Dr. Song Li. Tigermed would retain Frontage's China business. The transaction remains subject to conditions precedent.